Search
01/09/2021
Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis
Villanueva, C, Albillos, A, Genesca, J, Garcia-Pagan, JC, Brujats, A, Calleja, JL, Aracil, C, Banares, R, Morillas, RM, Poca, M, Penas, B, Augustin, S, Abraldes, JG, Alvarado, E, Torres, F, Bosch, J. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. JOURNAL OF HEPATOLOGY. 2021; 75(3)DOI:10.1016/j.jhep.2021.04.022. PMID:33905794. IF:30.083(Q1/1D).
01/09/2021
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Ampuero, J, Aller, R, Gallego-Duran, R, Crespo, J, Abad, J, Gonzalez-Rodriguez, A, Gomez-Camarero, J, Caballeria, J, Lo Iacono, O, Ibanez, L, Garcia-Samaniego, J, Martin-Mateos, R, Frances, R, Fernandez-Rodriguez, C, Diago, M, Soriano, G, Andrade, RJ, Latorre, R, Jorquera, F, Morillas, RM, Escudero, D, Estevez, P, Hernandez-Guerra, M, Augustin, S, Pareja-Megia, MJ, Banales, JM, Aspichueta, P, Benlloch, S, Rosales, JM, Salmeron, J, Turnes, J, Romero-Gomez, M. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. LIVER INTERNATIONAL. 2021; 41(9)DOI:10.1111/liv.14898. PMID:33896100. IF:8.754(Q1/2D).
01/09/2021
Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study
Murillo-Saich, JD, Diaz-Torne, C, Ortiz, MA, Coras, R, Gil-Alabarse, P, Pedersen, A, Corominas, H, Vidal, S, Guma, M. Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study. Metabolomics. 2021; 17(9)DOI:10.1007/s11306-021-01822-2. PMID:34402961. IF:4.747(Q2/4D).
01/09/2021
Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD
de-Torres, JP, O'Donnell, DE, Marin, JM, Cabrera, C, Casanova, C, Marin, M, Ezponda, A, Cosio, BG, Martinez, C, Solanes, I, Fuster, A, Neder, JA, Gonzalez-Gutierrez, J, Celli, BR. Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. CHEST. 2021; 160(3)DOI:10.1016/j.chest.2021.04.033. PMID:33901498. IF:11.393(Q1/1D).
01/09/2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
Gonzalez-Cordon, A, Assoumou, L, Moyle, G, Waters, L, Johnson, M, Domingo, P, Fox, J, Stellbrink, HJ, Guaraldi, G, Masia, M, Gompels, M, De Wit, S, Florence, E, Esser, S, Raffi, F, Behrens, G, Pozniak, A, Gatell, JM, Martinez, E. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(9)DOI:10.1093/jac/dkab158. PMID:34120186. IF:5.758(Q1/2D).
01/09/2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Blackhall, F, Jao, K, Greillier, L, Cho, BC, Penkov, K, Reguart, N, Majem, M, Nackaerts, K, Syrigos, K, Hansen, K, Schuette, W, Cetnar, J, Cappuzzo, F, Okamoto, I, Erman, M, Langer, SW, Kato, T, Groen, H, Sun, ZW, Luo, Y, Tanwani, P, Caffrey, L, Komarnitsky, P, Reinmuth, N. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology. 2021; 16(9)DOI:10.1016/j.jtho.2021.02.009. PMID:33607312. IF:20.121(Q1/1D).